CEL-SCI Announces Bought Deal Offering
VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced today that it has entered
Read moreCel-Sci
How do pharmaceutical companies profit from COVID-19? (do they?)
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?
Read moreCEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study
VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal
Read more